| Aug 15 |
FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication
|
| Aug 14 |
Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)
|
| Aug 14 |
FDA approves Incyte's Niktimvo for chronic graft-versus-host disease
|
| Aug 12 |
Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia
|
| Aug 3 |
Despite currently being unprofitable, Syndax Pharmaceuticals (NASDAQ:SNDX) has delivered a 113% return to shareholders over 5 years
|
| Aug 2 |
Syndax Pharmaceuticals, Inc. (SNDX) Q2 2024 Earnings Call Transcript
|
| Aug 1 |
Syndax: Q2 Earnings Snapshot
|
| Aug 1 |
Syndax Pharmaceuticals GAAP EPS of -$0.80 beats by $0.11
|
| Aug 1 |
Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update
|
| Aug 1 |
Syndax's revumenib granted FDA orphan drug designation for leukemia
|
